- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | CAMBIUM BIO LIMITED: Change of Directors Interest Notice - ST | 1 | ASX | ||
| 16.03. | CAMBIUM BIO LIMITED: Cleansing Notice | - | ASX | ||
| 16.03. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | - | ASX | ||
| 16.03. | CAMBIUM BIO LIMITED: Results of General Meeting | 1 | ASX | ||
| CAMBIUM BIO Aktie jetzt für 0€ handeln | |||||
| 19.02. | CAMBIUM BIO LIMITED: Half Year Report and Accounts | - | ASX | ||
| 11.02. | CAMBIUM BIO LIMITED: Notice of General Meeting/Proxy Form | - | ASX | ||
| 11.02. | CAMBIUM BIO LIMITED: Proposed issue of securities - CMB | - | ASX | ||
| 22.01. | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 19.01. | CAMBIUM BIO LIMITED: Proposed issue of securities - CMB | - | ASX | ||
| 19.01. | CAMBIUM BIO LIMITED: Cambium Bio Secures A$2.4 Million Strategic Investment | - | ASX | ||
| 27.10.25 | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 27.10.25 | CAMBIUM BIO LIMITED: Corrective Appendix 3Y Terrence Walts | 1 | ASX | ||
| 23.10.25 | CAMBIUM BIO LIMITED: Change of Directors Interest Notice - TW | - | ASX | ||
| 23.10.25 | CAMBIUM BIO LIMITED: Change of Directors Interest Notice - EW | - | ASX |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,610 | -0,85 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| VERA THERAPEUTICS | 43,450 | -2,10 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDGEWISE THERAPEUTICS | 33,700 | +1,78 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| ARCELLX | 115,00 | +0,10 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| EVOTEC | 5,545 | +2,88 % | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,970 | +4,11 % | Piper Sandler reiterates Nurix stock rating on CLL drug outlook | ||
| ALUMIS | 24,160 | +5,59 % | H.C. Wainwright reiterates Alumis stock rating, $25 target | ||
| ALLOGENE THERAPEUTICS | 2,165 | -5,04 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,270 | +1,64 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| ERASCA | 18,195 | +2,05 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| MINERALYS THERAPEUTICS | 30,420 | +11,47 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,330 | +5,23 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | - Matthew Gall appointed Chief Financial Officer -- Additional key appointments add expertise in clinical operations, corporate strategy and project leadership - BOSTON, April 15, 2026 (GLOBE... ► Artikel lesen | |
| BIONTECH | 84,65 | +0,42 % | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,995 | +27,28 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update | Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 339,71 | -1,02 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen |
Das Unternehmen CAMBIUM BIO LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMBIUM BIO LIMITED finden Sie auf Wallstreet Online.